Concepedia

Claudio Savulsky

CS

8

Publications

345

Citations

8

H-Index

1995

Active since

Affiliations

Eisai (United States)(Current)

Eisai (United Kingdom)

Dana-Farber Cancer Institute

Rocky Mountain Cancer Centers

Merck & Co., Inc., Rahway, NJ, USA (United States)

Claudio Savulsky is an author at Eisai (United States) specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

1995–2021

8

Publications

8

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani et al. · Clinical Cancer Research · 2021 · 134 citations · Full text

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

SM Tolaney, Kevin Kalinsky, Virginia Kaklamani et al. · Cancer Research · 2018 · 71 citations

, , +18

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

SM Tolaney, Claudio Savulsky, Gursel Aktan et al. · European Journal of Cancer · 2017 · 40 citations

, , +8

Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter study

Michael Marberger, Amir V. Kaisary, Neal D. Shore et al. · Clinical Therapeutics · 2010 · 39 citations

, , +7

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

T.R. Jeffry Evans, Emma Dean, L Rhoda Molife et al. · British Journal of Cancer · 2019 · 22 citations · Full text

Rows per page

1–5 of 8